Skip to main content

Table 1 Patient, donor and transplants characteristics

From: Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies

Patient characteristics Intensified myeloablative conditioning (n = 81) Standard myeloablative conditioning (n = 104) P-value
Female/Male 31(38.3%)/50(61.7%) 41(39.4%)/63(60.6%) NS
Median age, years (range) 26(14–54) 28(12–63) NS
Disease    
  ALL 42 (51.85%) 23 (22.1%) P<0.001
  AML 17 (21.0%) 43(41.4%)  
  ALAL 12 (14.8%) 12 (11.5%)  
  CML 6 (7.4%) 22 (21.2%)  
  HD/NHL 3(3.7%) 2 (1.9%)  
  MDS 0 (0%) 2 (1.9%)  
  BPDCN 1 (1.25%) 0 (0%)  
Disease status at the time of transplants    
  CR (including CML-CP) 31 (38.3%) 94 (90.4%) P<0.001
  NR (including CML-AP and BC) 50 (61.7%) 10 (9.6%)  
EBV serostatus    
  D-/R- 15(18.5 %) 21(20.2 %) NS
  D+/R- 23(28.4%) 27(26.0%)  
  D-/R+ 16(19.8%) 22(21.1%)  
  D+/R+ 27(33.3%) 34(32.7%)  
CMV serostatus    
  D-/R- 4(4.9%) 5(4.8%) NS
  D+/R- 3(3.7%) 4(3.85%)  
  D-/R+ 3(3.7%) 2(1.95%)  
  D+/R+ 71(87.7%) 93(89.4%)  
Donor type    
  Sibling donor 44(54.3%) 73 (70.2%) P = 0.010
  Family donor 11 (13.6%) 3 (2.9%)  
  Unrelated donor 26(32.1%) 28 (26.9%)  
HLA typing    
  HLA-identical 49 (60.5%) 79 (76.0%) NS
  One allele mismatched 15 (18.5%) 15 (14.4%)  
  Two alleles mismatched 8 (9.9%) 8 (7.7%)  
  Three alleles mismatched 1 (1.2%) 1 (0.95%)  
  Four alleles mismatched 6 (7.4%) 1 (0.95%)  
  Five alleles mismatched 2 (2.5%) 0 (0.0%)  
Stem cell source    
  PBSCs 63 (77.8%) 90 (86.5%) NS
  BM 1 (1.2%) 0 (0.0%)  
  PBSCs + BM 17(21.0%) 14 (13.5%)  
Median CD34+ cells per graft, ×106/kg (range) 8.8(5.4-11.9) 8.1(5.2-11.7) NS
Conditioning    
  TBI + CY   36 (34.6%) NA
  Bu + CY   40 (38.5%)  
  Bu + Flu   28(26.9%)  
  Flu + Ara-c + TBI + CY 49 (60.5%)   
  TBI + CY + VP-16 32 (39.5%)   
GVHD prophylaxis    
  CsA 4 (5.0%) 2 (1.9%) NS
  CsA + MTX 33 (40.75%) 62 (59.6%)  
  CsA + MTX + ATG 28 (34. 5%) 27 (26.0%)  
  CsA + MTX + MMF 3 (3.7%) 2 (1.9%)  
  CsA + MTX + ATG + MMF 13 (16.05%) 11 (10.6%)  
  1. ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; ALAL = acute leukemia of ambiguous lineage; CML = chronic myelogenous leukemia; HD = Hodgkin’s disease; NHL = Non-Hodgkin’s lymphoma; MDS = myelodysplastic syndromes; BPDCN = blastic plasmacytoid dendritic cell neoplasm;CR = complete remission; CP = chronic phase; NR = not in CR; AP = accelerated phase; BC = blastic crisis; D = donor; R = recipient; PBSCs = peripheral blood stem cells; BM = bone marrow; TBI = total body irradiation; CY = cyclophosphamide; BU = busulfan; FLU = fludarabine; Ara-c = cytarabine; VP16 = etoposide; GVHD = graft-versus-host disease; CSA = cyclosporine A; MTX = methotrexate; ATG = antithymocyte globulin; MMF = mycophenolate mofetil; NS = not significant; NA = not applicable.